Toxicogenomics Market (2026-2036)

The growth of this market is mainly driven by regulatory initiatives to reduce animal testing and accept new approach methodologies in drug and chemical safety assessment, the high attrition of drug candidates due to safety failures and the need for earlier and more predictive toxicity assessment, the declining cost and increasing throughput of sequencing and targeted transcriptomics, and the growing use of transcriptomic points of departure and mechanistic data in chemical risk assessment. In addition, the integration of toxicogenomics with human cell-based models, organoids, and organ-on-chip systems, the application of artificial intelligence (AI) to toxicogenomic data, the development of international reporting frameworks and public toxicogenomic databases, and the growing safety assessment needs of cosmetics, agrochemicals, and industrial chemicals are further supporting the growth of this market.

The Toxicogenomics Market, also referred to as the toxicogenomic testing market, omics-based toxicology market, or genomic toxicology market, comprises the reagents and kits, instruments, software and databases, and services used to measure changes in gene expression and other molecular responses to drugs, chemicals, and environmental agents in order to identify hazards, understand mechanisms of toxicity, and support safety assessment. The market includes whole-transcriptome RNA sequencing; targeted and high-throughput transcriptomics, such as templated oligo sequencing and reduced gene sets; gene expression microarrays; quantitative PCR (qPCR) panels for toxicity biomarkers; error-corrected DNA sequencing for mutagenicity assessment; epigenomic, proteomic, and metabolomic profiling as part of multi-omics toxicology; bioinformatics, benchmark dose modeling, and toxicogenomic databases; and toxicogenomic testing services provided by contract research organizations (CROs). The market ecosystem extends from manufacturers of sequencing, microarray, and PCR platforms and reagents to developers of targeted transcriptomic assays and software, CROs, pharmaceutical and biotechnology companies, chemical, agrochemical, and cosmetics companies, regulatory and government research agencies, and academic institutions.

Toxicogenomics addresses a fundamental problem in safety assessment. Traditional toxicity testing relies largely on animal studies that measure apical endpoints, such as organ damage or tumors, after long exposures, and these studies are expensive, slow, and often poorly predictive of human outcomes. According to the FDA, approximately 90% of drugs that pass animal studies are not approved because of safety or efficacy problems in humans. Toxicogenomic methods measure early molecular changes, often within days of exposure and in human cells, allowing toxic effects to be identified earlier, mechanisms to be understood, and compounds to be ranked by potency.

Regulatory change is the most important force reshaping the market. In April 2026, the U.S. Food and Drug Administration (FDA) reported that it had met the key first-year goals of its April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies, including draft guidance on reducing nonhuman primate testing for monoclonal antibodies, draft guidance on new approach methodologies (NAMs) published in March 2026 supporting a weight-of-evidence approach using in vitro assays and computational toxicology, a searchable database of alternative methods, and a formal partnership with the National Institutes of Health (NIH) to make human-relevant science the default approach to drug evaluation. In September 2026, the FDA announced a direct final rule replacing the terms "animal tests" and "animal studies" with "nonclinical tests" and "nonclinical studies" throughout its regulations, clarifying that non-animal methods can be used where appropriate to test the safety of drugs and biological products, and released a database of 25 use cases in which NAMs have already appeared in FDA review materials. These actions are expected to increase the use of in vitro, in silico, and molecular methods in drug development, and toxicogenomic data are a central part of the weight-of-evidence approach that the FDA is promoting.

Chemical safety assessment is undergoing a similar transition. In June 2026, the European Commission published its roadmap towards phasing out animal testing for chemical safety assessments, covering 15 regulatory domains including industrial and consumer chemicals, pesticides, biocides, pharmaceuticals, and food and feed additives, and noting that more than 15 million animals were used for regulatory testing in the EU between 2015 and 2023, nearly 40% of them for chemical safety assessments. In the U.S., the Environmental Protection Agency (EPA) has developed transcriptomic approaches for deriving points of departure for data-poor chemicals, and the Tox21 program, a collaboration between federal agencies, has generated high-throughput screening and transcriptomic data on thousands of chemicals. The Organisation for Economic Co-operation and Development (OECD) has published an omics reporting framework to support the regulatory use of transcriptomic and metabolomic data.

Technology advances are making toxicogenomics practical at scale. The cost of sequencing has fallen sharply, targeted transcriptomic methods allow thousands of samples to be profiled at low cost directly from cell lysates, and benchmark dose modeling software allows transcriptomic points of departure to be derived from concentration-response data. Human induced pluripotent stem cell-derived cells, three-dimensional organoids, and organ-on-chip systems provide more human-relevant test systems, and AI is being used to predict toxicity from gene expression signatures.

The market includes life science technology companies such as Thermo Fisher Scientific, Illumina, QIAGEN, and Agilent Technologies, which supply sequencing, microarray, PCR, and sample preparation products; developers of targeted transcriptomic platforms such as BioSpyder Technologies; and CROs such as Charles River Laboratories, Labcorp, Inotiv, and Eurofins Scientific, which provide toxicology and toxicogenomic services. These companies compete on the throughput and cost of profiling, data quality and reproducibility, the availability of validated toxicity signatures and reference databases, bioinformatics and interpretation, and regulatory experience.

At the same time, the market faces challenges, including the lack of fully validated and regulatory-accepted toxicogenomic methods for many endpoints, the difficulty of linking molecular changes to adverse outcomes, the complexity of analyzing and interpreting large omics datasets, and differences in study design and data analysis between laboratories. The financial pressure on CROs following reduced biotechnology funding has also affected demand for preclinical services. As a result, companies that combine high-throughput and cost-effective profiling, human-relevant test systems, validated signatures, robust bioinformatics, and support for regulatory submissions are expected to capture the largest share of growth over the forecast period.